Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Medicilon assists Ringene Biopharma 's SHP2 allosteric inhibitor RG001 tablet to be approved for clinical use

Page View:

Recently, Shanghai Ringene Biopharma (Ringene) announced that the company’s self-developed anti-tumor class I new drug SHP2 allosteric inhibitor RG001 tablet has been approved for clinical use.

Shanghai Medicilon Inc. (Medicilon) provides a range of preclinical services from drug targets to IND filing in the development of RG001 tablets to enter the clinical trial phase, including drug discovery, pharmaceutical research, and pre-clinical research (drug efficacy and safety evaluations).


RG001 tablet is a new SHP2 allosteric inhibitor independently developed by Ringene based on structural biology and drug metabolism-oriented drug design methods.  Preclinical studies have shown that RG001 specifically and efficiently inhibits SHP2 and SHP2 in nearly 500 different proteins and the activities of tyrosine phosphatase and its mutants.  The unique absorption, distribution and metabolism properties enable RG001 to show high-efficiency and long-lasting anti-tumor activity in a variety of tumor models carrying oncogenic mutations in the RTK/RAS pathway.  In addition, preclinical translational medicine studies have shown that RG001 has significant synergistic anti-tumor effects with a variety of targeted drugs and immune checkpoint inhibitor drugs, such as EGFR inhibitors, KRAS inhibitors, FAK inhibitors, PD-1/L1 antibodies, etc.

RG001 has a dual mechanism of targeting tumor growth and tumor immunity, and is expected to be used in the treatment of advanced solid tumors resistant to RTK-Ras-MAPK pathway and immune checkpoint inhibitor drugs and malignant hematomas with SHP2 mutations.

The research and development of innovative drugs is a complex engineering, and it has become a trend for pharmaceutical companies to outsource part of the research and development to professional CXO companies.  However, outsourcing to different CXO companies will lead to an increase of coordination cost such as labor cost.  In the research and development of RG001 tablets, Medicilon used the advantages of a one-stop research and development platform to seamlessly connect drug discovery, pharmaceutical research and preclinical research to greatly improve the integration of the project, shortening the research and development process, and significantly reduce the  R&D costs.  In addition, both parties have jointly established a team of new drug research and development experts to monitor the progress of research and development in real time basis and adjust the plan in time to ensure the high-quality and efficient completion of the project.

Collaboration accelerates innovation and gathers efforts to empower a win-win situation.  Medicilon congratulates Ringene on the staged success, and looks forward to the early launch of RG001, which will reignite the life of cancer patients, and also look forward to collaborating with more new drug developers to help the pharmaceutical industry.

About Ringene Biopharma

Ringene Biopharma is a biotechnology company focusing on the research and development of innovative drugs for the RTK-RAS-MAPK signaling pathway. It was co-founded by well-known medicinal chemists Professor Jingkang Shen and Dr. Huixin Wan.  The management team has extensive experience in drug design, translational medicine and project management. At the beginning of the company’s establishment, it was recognized by the well-known investment institutions such as SDIC Ventures Capital and Shenzhen Capital Group.

Ringene Biopharma is guided by clinical unmet needs and based on a drug design platform guided by structural biology, focusing on the key signaling proteins of RTK-RAS-MAPK pathway resistance, Ringene has established a rich pipeline of preclinical drug candidates.  A number of new drugs will be advanced to the clinical stage in the future, which is expected to provide a variety of single-drug or combined-drug solutions for patients with clinical tumor resistance.

About Medicilon

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China.  Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  Medicilon grows together with the clients and delivers the new drug research and development services to more than 900 clients globally.  Medicilon is proud to contribute to human health in the globe.

Relevant newsRelevant news